Mitsubishi UFJ Asset Management
FATE icon

Mitsubishi UFJ Asset Management’s Fate Therapeutics FATE Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-71,101
Closed -$249K – 1598
2024
Q3 		$249K Sell
71,101
-6,715
-9% -$26.1K ﹤0.01% 937
2024
Q2 		$255K Buy
+77,816
New +$341K ﹤0.01% 932
2023
Q4 		– Sell
-60,299
Closed -$128K – 1569
2023
Q3 		$128K Buy
60,299
+7,916
+15% +$26.2K ﹤0.01% 1059
2023
Q2 		$249K Buy
52,383
+39,734
+314% +$219K ﹤0.01% 1012
2023
Q1 		$72.1K Hold
12,649
– – ﹤0.01% 1100
2022
Q4 		$129K Buy
12,649
+1,597
+14% +$30K ﹤0.01% 1065
2022
Q3 		$248K Sell
11,052
-19
-0.2% -$549 ﹤0.01% 1000
2022
Q2 		$274K Buy
11,071
+5,511
+99% +$152K ﹤0.01% 1007
2022
Q1 		$216K Buy
5,560
+330
+6% +$12.8K ﹤0.01% 1043
2021
Q4 		$315K Buy
5,230
+1,119
+27% +$63.4K ﹤0.01% 1001
2021
Q3 		$244K Hold
4,111
– – ﹤0.01% 1033
2021
Q2 		$357K Sell
4,111
-3,047
-43% -$246K ﹤0.01% 1005
2021
Q1 		$590K Buy
7,158
+2,325
+48% +$223K ﹤0.01% 861
2020
Q4 		$439K Sell
4,833
-1,843
-28% -$114K ﹤0.01% 848
2020
Q3 		$267K Sell
6,676
-42
-0.6% -$1.47K ﹤0.01% 863
2020
Q2 		$230K Sell
6,718
-5,537
-45% -$165K ﹤0.01% 869
2020
Q1 		$272K Buy
12,255
+2,480
+25% +$62.7K ﹤0.01% 815
2019
Q4 		$187K Buy
9,775
+1,955
+25% +$31K ﹤0.01% 881
2019
Q3 		$121K Buy
7,820
+1,529
+24% +$29.3K ﹤0.01% 882
2019
Q2 		$128K Sell
6,291
-6,333
-50% -$114K ﹤0.01% 893
2019
Q1 		$222K Buy
12,624
+1,139
+10% +$18K ﹤0.01% 783
2018
Q4 		$151K Sell
11,485
-3,116
-21% -$43.4K ﹤0.01% 787
2018
Q3 		$238K Buy
+14,601
New +$173K ﹤0.01% 756

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Mitsubishi UFJ Asset Management's FATE Position: Q4 2024 in Review

Mitsubishi UFJ Asset Management sold out of Fate Therapeutics (FATE) in Q4 2024, closing a stake of 71,101 shares — an estimated $249K sold.

Mitsubishi UFJ Asset Management first reported a position in FATE in Q3 2018 and held it in 23 quarters. The position peaked at $590K in Q1 2021. 159 funds tracked by Wall St. Rank hold FATE as of Q4 2024.

  • Mitsubishi UFJ Asset Management reported no remaining Fate Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 71,101 Fate Therapeutics shares in Q4 2024, an estimated $249K.
  • Mitsubishi UFJ Asset Management first reported a position in Fate Therapeutics in Q3 2018 and held it in 23 quarters.
  • Mitsubishi UFJ Asset Management's Fate Therapeutics position peaked at $590K in Q1 2021.
  • 159 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2024.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.